CST, 64991SF, Cyclin D1 (DCS6) Mouse Monoclonal Antibody (BSA and Azide Free)

Monoclonal Antibody for studying Cyclin D1. Validated for Western Blotting,ELISA+. Highly specific and rigorously validated in-house, Cyclin D1 (DCS6) Mouse Monoclonal Antibody (BSA and Azide Free) (CST #64991) is ready to ship. Product Usage Information This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, please contact us . Optimal dilutions/concentrations should be determined by the end user. BSA and Azide Free antibodies are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity. Formulation Supplied in 1X PBS (10 mM Na 2 HPO 4 , 3 mM KCl, 2 mM KH 2 PO 4 , and 140 mM NaCl (pH 7.8)). BSA and Azide Free. Storage Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance. Specificity / Sensitivity Cyclin D1 (DCS6) Mouse Monoclonal Antibody (BSA and Azide Free) detects endogenous levels of total cyclin D1 protein. This antibody does not cross-react with cyclin D2 or D3. Species Reactivity: Human, Mouse, Rat, Monkey Source / Purification Monoclonal antibody is produced by immunizing animals with recombinant human cyclin D1 corresponding to residues 151-170. Background Activity of the cyclin-dependent kinases CDK4 and CDK6 is regulated by T-loop phosphorylation, by the abundance of their cyclin partners (the D-type cyclins), and by association with CDK inhibitors of the Cip/Kip or INK family of proteins (1). The inactive ternary complex of cyclin D/CDK4 and p27 Kip1 requires extracellular mitogenic stimuli for the release and degradation of p27 concomitant with a rise in cyclin D levels to affect progression through the restriction point and Rb-dependent entry into S-phase (2). The active complex of cyclin D/CDK4 targets the retinoblastoma protein for phosphorylation, allowing the release of E2F transcription factors that activate G1/S-phase gene expression (3). Levels of cyclin D protein drop upon withdrawal of growth factors through downregulation of protein expression and phosphorylation-dependent degradation (4). Of the three D cyclins, aberrant expression of cyclin D1 has been associated with many forms of cancer including B cell lymphomas and can directly contribute to oncogenesis by various mechanisms including gene translocation or amplification (2). Cyclin D1 also plays a critical role in mammary tissue maturation (5). Alternate Names B-cell CLL/lymphoma 1; B-cell lymphoma 1 protein; BCL-1; BCL-1 oncogene; BCL1; CCND1; CycD1; cyclin D1; D11S287E; G1/S-specific cyclin D1; G1/S-specific cyclin-D1; PRAD1; PRAD1 oncogene; U21B31 Specification REACTIVITY: H M R Mk SENSITIVITY: Endogenous MW (kDa): 36 Source/Isotype: Mouse IgG2a